MGX supply chain intelligence for Metagenomi Therapeutics, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Metagenomi Therapeutics, Inc. (MGX) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| IONIS | IONIS | 92% | The Company will manufacture all licensed systems and certain components of the applicable licensed products that are needed by Ionis for use in its development activities and all of the Company’s ma… |
| CRBU | Caribou Biosciences, Inc. | 72% | Reciprocal relationship from CRBU graph: cts from countries where our product candidates may be sold at lower prices than in the United States. 60 Table of Contents Third-party payors, whether domest… |
| CRBU | Caribou Biosciences, Inc. | 72% | amples of any lot of any approved product together with the protocols showing the results of applicable tests at any time. Under some circumstances, the FDA, the EMA or other regulatory authorities m… |
| CRSP | CRISPR Therapeutics AG | 72% | Reciprocal relationship from CRSP graph: Reciprocal relationship from MGX graph: Reciprocal relationship from CRSP graph: Reciprocal relationship from MGX graph: amples of any lot of any approved pro… |
| CRSP | CRISPR Therapeutics AG | 72% | amples of any lot of any approved product together with the protocols showing the results of applicable tests at any time. Under some circumstances, the FDA, the EMA or other regulatory authorities m… |
| DTIL | Precision BioSciences, Inc. | 72% | amples of any lot of any approved product together with the protocols showing the results of applicable tests at any time. Under some circumstances, the FDA, the EMA or other regulatory authorities m… |
| DTIL | Precision BioSciences, Inc. | 72% | Reciprocal relationship from DTIL graph: Reciprocal relationship from MGX graph: amples of any lot of any approved product together with the protocols showing the results of applicable tests at any t… |
| EDIT | Editas Medicine, Inc. | 72% | amples of any lot of any approved product together with the protocols showing the results of applicable tests at any time. Under some circumstances, the FDA, the EMA or other regulatory authorities m… |
| EDIT | Editas Medicine, Inc. | 72% | Reciprocal relationship from EDIT graph: Reciprocal relationship from MGX graph: amples of any lot of any approved product together with the protocols showing the results of applicable tests at any t… |
| IONS | Ionis Pharmaceuticals, Inc. | 72% | elopment, manufacture and commercialization of programs or product candidates. If these collaborations are not successful, our business could be adversely affected. As part of our strategy, we have e… |
| IONS | Ionis Pharmaceuticals, Inc. | 72% | Reciprocal relationship from IONS graph: Reciprocal relationship from MGX graph: Reciprocal relationship from IONS graph: Reciprocal relationship from MGX graph: Reciprocal relationship from IONS gra… |
| LLY | Eli Lilly and Company | 72% | Reciprocal relationship from LLY graph: Reciprocal relationship from MGX graph: Reciprocal relationship from LLY graph: Reciprocal relationship from MGX graph: Reciprocal relationship from LLY graph:… |
| MYGN | Myriad Genetics, Inc. | 72% | Reciprocal relationship from MYGN graph: Reciprocal relationship from MGX graph: ring passwords for our computers. Additionally, we execute confidentiality agreements with any third parties to whom w… |
| MYGN | Myriad Genetics, Inc. | 72% | ring passwords for our computers. Additionally, we execute confidentiality agreements with any third parties to whom we may provide access to the information and with our employees, consultants, scie… |
| NTLA | Intellia Therapeutics, Inc. | 72% | Reciprocal relationship from NTLA graph: devices, requiring detailed risk management and review processes to obtain approvals. If we use AI systems governed by these laws or regulations, we will need… |
| NTLA | Intellia Therapeutics, Inc. | 72% | amples of any lot of any approved product together with the protocols showing the results of applicable tests at any time. Under some circumstances, the FDA, the EMA or other regulatory authorities m… |
| QURE | uniQure N.V. | 72% | Reciprocal relationship from QURE graph: Reciprocal relationship from MGX graph: evenue and achieve or maintain profitability; • the level of taxes that we are required to pay; and • the availability… |
| QURE | uniQure N.V. | 72% | evenue and achieve or maintain profitability; • the level of taxes that we are required to pay; and • the availability of capital. Any reduction in reimbursement from Medicare or other government pro… |
| SGMO | Sangamo Therapeutics, Inc. | 72% | amples of any lot of any approved product together with the protocols showing the results of applicable tests at any time. Under some circumstances, the FDA, the EMA or other regulatory authorities m… |
| SGMO | Sangamo Therapeutics, Inc. | 72% | Reciprocal relationship from SGMO graph: Reciprocal relationship from MGX graph: amples of any lot of any approved product together with the protocols showing the results of applicable tests at any t… |
| SNYNF | Sanofi | 72% | ring passwords for our computers. Additionally, we execute confidentiality agreements with any third parties to whom we may provide access to the information and with our employees, consultants, scie… |
| SNYNF | Sanofi | 72% | Reciprocal relationship from SNYNF graph: Reciprocal relationship from MGX graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from MGX graph: Reciprocal relationship from SNYNF … |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| IONS | Ionis Pharmaceuticals, Inc. | 85% | elopment, manufacture and commercialization of programs or product candidates. If these collaborations are not successful, our business could be adversely affected. As part of our strategy, we have e… |
| IONS | Ionis Pharmaceuticals, Inc. | 85% | Reciprocal relationship from IONS graph: Reciprocal relationship from MGX graph: Reciprocal relationship from IONS graph: Reciprocal relationship from MGX graph: Reciprocal relationship from IONS gra… |
| CRBU | Caribou Biosciences, Inc. | 72% | Reciprocal relationship from CRBU graph: cts from countries where our product candidates may be sold at lower prices than in the United States. 60 Table of Contents Third-party payors, whether domest… |
| CRBU | Caribou Biosciences, Inc. | 72% | amples of any lot of any approved product together with the protocols showing the results of applicable tests at any time. Under some circumstances, the FDA, the EMA or other regulatory authorities m… |
| CRSP | CRISPR Therapeutics AG | 72% | Reciprocal relationship from CRSP graph: Reciprocal relationship from MGX graph: amples of any lot of any approved product together with the protocols showing the results of applicable tests at any t… |
| CRSP | CRISPR Therapeutics AG | 72% | amples of any lot of any approved product together with the protocols showing the results of applicable tests at any time. Under some circumstances, the FDA, the EMA or other regulatory authorities m… |
| DTIL | Precision BioSciences, Inc. | 72% | amples of any lot of any approved product together with the protocols showing the results of applicable tests at any time. Under some circumstances, the FDA, the EMA or other regulatory authorities m… |
| DTIL | Precision BioSciences, Inc. | 72% | Reciprocal relationship from DTIL graph: Reciprocal relationship from MGX graph: amples of any lot of any approved product together with the protocols showing the results of applicable tests at any t… |
| EDIT | Editas Medicine, Inc. | 72% | Reciprocal relationship from EDIT graph: Reciprocal relationship from MGX graph: Reciprocal relationship from EDIT graph: Reciprocal relationship from MGX graph: Reciprocal relationship from EDIT gra… |
| EDIT | Editas Medicine, Inc. | 72% | amples of any lot of any approved product together with the protocols showing the results of applicable tests at any time. Under some circumstances, the FDA, the EMA or other regulatory authorities m… |
| LLY | Eli Lilly and Company | 72% | Reciprocal relationship from LLY graph: Reciprocal relationship from MGX graph: Reciprocal relationship from LLY graph: Reciprocal relationship from MGX graph: amples of any lot of any approved produ… |
| LLY | Eli Lilly and Company | 72% | amples of any lot of any approved product together with the protocols showing the results of applicable tests at any time. Under some circumstances, the FDA, the EMA or other regulatory authorities m… |
| NTLA | Intellia Therapeutics, Inc. | 72% | amples of any lot of any approved product together with the protocols showing the results of applicable tests at any time. Under some circumstances, the FDA, the EMA or other regulatory authorities m… |
| NTLA | Intellia Therapeutics, Inc. | 72% | Reciprocal relationship from NTLA graph: Reciprocal relationship from MGX graph: Reciprocal relationship from NTLA graph: Reciprocal relationship from MGX graph: Reciprocal relationship from NTLA gra… |
| QURE | uniQure N.V. | 72% | evenue and achieve or maintain profitability; • the level of taxes that we are required to pay; and • the availability of capital. Any reduction in reimbursement from Medicare or other government pro… |
| QURE | uniQure N.V. | 72% | Reciprocal relationship from QURE graph: Reciprocal relationship from MGX graph: Reciprocal relationship from QURE graph: Reciprocal relationship from MGX graph: evenue and achieve or maintain profit… |
| SGMO | Sangamo Therapeutics, Inc. | 72% | amples of any lot of any approved product together with the protocols showing the results of applicable tests at any time. Under some circumstances, the FDA, the EMA or other regulatory authorities m… |
| SGMO | Sangamo Therapeutics, Inc. | 72% | Reciprocal relationship from SGMO graph: Reciprocal relationship from MGX graph: Reciprocal relationship from SGMO graph: Reciprocal relationship from MGX graph: Reciprocal relationship from SGMO gra… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| MGX-DEBT | Debt stack $39.2M | 90% | Market cache reports total debt of $39.2M. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| MGX-OWNER-VANGUARD-CAPITAL-MANAGEMENT-LLC | VANGUARD CAPITAL MANAGEMENT LLC | 90% | 13F overlay lists VANGUARD CAPITAL MANAGEMENT LLC as top holder; 51 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| LGND | Ligand Pharmaceuticals Incorporated | 100.00 | 2 | |
| ALNY | Alnylam Pharmaceuticals, Inc. | 100.00 | 2 | |
| AKTS | Aktis Oncology, Inc. | 100.00 | 2 | |
| BCYC | Bicycle Therapeutics plc | 100.00 | 2 | |
| EDIT | Editas Medicine, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| REGN | Regeneron Pharmaceuticals, Inc. | 100.00 | 2 | |
| DSGN | Design Therapeutics, Inc. | 100.00 | 2 | |
| DTIL | Precision BioSciences, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| EDSA | Edesa Biotech, Inc. | 100.00 | 2 | |
| DAWN | Day One Biopharmaceuticals Inc | 100.00 | 2 | |
| CRBU | Caribou Biosciences, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| CTNM | Contineum Therapeutics, Inc. | 100.00 | 2 | |
| ALLO | Allogene Therapeutics, Inc. | 100.00 | 2 | |
| NVO | Novo Nordisk A/S | 100.00 | 2 | |
| BIOA | BioAge Labs, Inc. | 100.00 | 2 | |
| BDRX | Biodexa Pharmaceuticals Plc | 100.00 | 2 | |
| FHTX | Foghorn Therapeutics Inc. | 100.00 | 2 | |
| BEAM | Beam Therapeutics Inc. | 100.00 | 2 | |
| AXSM | Axsome Therapeutics, Inc. | 100.00 | 2 | |
| SDGR | Schrödinger, Inc. | 100.00 | 2 |